by Madaline Spencer | Jul 8, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic (linvoseltamab-gcpt) for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome...
by Madaline Spencer | Jul 8, 2025
Mike Flanagan, PhD, Chief Scientific Officer at Avidity Biosciences, discusses topline results from study testing delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy and the newly initiated phase 3 trial. FSHD is a rare...
by Madaline Spencer | Jul 7, 2025
The U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion) for patients ages two years and older with primary immunodeficiencies. Primary immunodeficiencies are a group of rare, genetic diseases affecting the immune...
by Madaline Spencer | Jul 7, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at Università Vita-Salute San Raffaele in Milan, Italy, discusses results from clinical trial testing ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)....
by Madaline Spencer | Jul 5, 2025
Marc Rothenberg, MD, of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), and Professor of Medicine at Cincinnati Children’s Hospital, gives an overview of eosinophilic esophagitis (EoE). CEGIR is part of the Rare Diseases...
